BRCA2 and ovarian cancer: According to the NCCN guideline, BRCA1, BRCA2, BRIP1, RAD51C and RAD51D have been proved with susceptibilities of ovarian cancer, and their deleterious mutation carriers were recommended for risk reducing salpingo-oophorectomy (RRSO) [6].